Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0M3GQ
|
||||
Former ID |
DIB013947
|
||||
Drug Name |
BL-22
|
||||
Synonyms |
CAT-3888; GCR-3888; RFB4(dsFv)-PE38; PE38-conjugated anti-CD22 immunotoxin, NCI/Cambridge Antibody Technology/AstraZeneca
|
||||
Drug Type |
Antibody
|
||||
Indication | Acute lymphoblastic leukemia [ICD9: 204.0, 556; ICD10:C91.0] | Phase 2 | [522698] | ||
Company |
National Cancer Institute
|
||||
Target and Pathway | |||||
Target(s) | B-cell receptor CD22 | Target Info | [530776] | ||
PANTHER Pathway | B cell activation | ||||
Pathway Interaction Database | BCR signaling pathway | ||||
WikiPathways | B Cell Receptor Signaling Pathway | ||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.